Institution
University of Patras
Education•Pátrai, Greece•
About: University of Patras is a education organization based out in Pátrai, Greece. It is known for research contribution in the topics: Population & Catalysis. The organization has 13372 authors who have published 31263 publications receiving 677159 citations. The organization is also known as: Panepistímio Patrón.
Topics: Population, Catalysis, Finite element method, Nonlinear system, Graphene
Papers published on a yearly basis
Papers
More filters
••
TL;DR: The aim of the current review is to summarize the strategies and the novel techniques adopted to enhance the viability of probiotics.
Abstract: Preserving the efficacy of probiotic bacteria exhibits paramount challenges that need to be addressed during the development of functional food products. Several factors have been claimed to be responsible for reducing the viability of probiotics including matrix acidity, level of oxygen in products, presence of other lactic acid bacteria, and sensitivity to metabolites produced by other competing bacteria. Several approaches are undertaken to improve and sustain microbial cell viability, like strain selection, immobilization technologies, synbiotics development etc. Among them, cell immobilization in various carriers, including composite carrier matrix systems has recently attracted interest targeting to protect probiotics from different types of environmental stress (e.g., pH and heat treatments). Likewise, to successfully deliver the probiotics in the large intestine, cells must survive food processing and storage, and withstand the stress conditions encountered in the upper gastrointestinal tract. Hence, the appropriate selection of probiotics and their effective delivery remains a technological challenge with special focus on sustaining the viability of the probiotic culture in the formulated product. Development of synbiotic combinations exhibits another approach of functional food to stimulate the growth of probiotics. The aim of the current review is to summarize the strategies and the novel techniques adopted to enhance the viability of probiotics.
352 citations
••
TL;DR: The process of lipid accumulation in the oleaginous yeasts cultivated in various fermentation configurations when either sugars and related compounds or hydrophobic substances are used as substrates is presented and kinetic models describing both de novo and ex novo lipid accumulation are analyzed.
Abstract: The process of lipid accumulation in the oleaginous yeasts cultivated in various fermentation configurations when either sugars and related compounds or hydrophobic substances are used as substrates is presented and kinetic models describing both de novo and ex novo lipid accumulation are analyzed. Technological aspects related with single cell oil (SCO) produced by oleaginous yeasts are depicted. The influence of culture parameters upon lipid production process is presented. Lipid production has been studied in batch, fed-batch, and continuous cultivation systems using yeasts belonging to the species Lipomyces starkeyi, Rhodosporidium toruloides, Apiotrichum curvatum, Candida curvata, Cryptococcus curvatus, Trichosporon fermentans, and Yarrowia lipolytica. The potentiality of yeasts to produce SCO as starting material of 2nd generation biodiesel is indicated and discussed. Of significant importance is also the utilization of yeast lipids as substitutes of high added value exotic fats (e.g., cocoa butter). Lipid produced by the various yeasts presents, in general, similar composition with that of common vegetable oils being composed of unsaturated fatty acids, whereas cocoa butter is principally composed of saturated fatty acids, consequently the various strategies that are followed in order to increase the cellular saturated fatty acid content of the yeast lipid are presented and comprehensively discussed.
350 citations
••
TL;DR: This work reviews recent findings that deal with genes associated with disease expression, immune cell molecular abnormalities that lead to autoimmune pathology, and the role of hormones and sex chromosomes in the development of disease.
349 citations
••
National and Kapodistrian University of Athens1, Athens Regional Medical Center2, Aristotle University of Thessaloniki3, Democritus University of Thrace4, University of Ioannina5, Alexandra Hospital6, University of Patras7, Instituto Politécnico Nacional8, Yale University9, Icahn School of Medicine at Mount Sinai10
TL;DR: A role for colchicine in the treatment of patients with coronavirus disease 2019 is suggested, with results suggesting a smaller increase in dimerized plasma fragment D compared with patients in the control group.
Abstract: Importance Severe acute respiratory syndrome coronavirus 2 infection has evolved into a global pandemic Low-dose colchicine combines anti-inflammatory action with a favorable safety profile Objective To evaluate the effect of treatment with colchicine on cardiac and inflammatory biomarkers and clinical outcomes in patients hospitalized with coronavirus disease 2019 (COVID-19) Design, Setting, and Participants In this prospective, open-label, randomized clinical trial (the Greek Study in the Effects of Colchicine in COVID-19 Complications Prevention), 105 patients hospitalized with COVID-19 were randomized in a 1:1 allocation from April 3 to April 27, 2020, to either standard medical treatment or colchicine with standard medical treatment The study took place in 16 tertiary hospitals in Greece Intervention Colchicine administration (15-mg loading dose followed by 05 mg after 60 min and maintenance doses of 05 mg twice daily) with standard medical treatment for as long as 3 weeks Main Outcomes and Measures Primary end points were (1) maximum high-sensitivity cardiac troponin level; (2) time for C-reactive protein to reach more than 3 times the upper reference limit; and (3) time to deterioration by 2 points on a 7-grade clinical status scale, ranging from able to resume normal activities to death Secondary end points were (1) the percentage of participants requiring mechanical ventilation, (2) all-cause mortality, and (3) number, type, severity, and seriousness of adverse events The primary efficacy analysis was performed on an intention-to-treat basis Results A total of 105 patients were evaluated (61 [581%] men; median [interquartile range] age, 64 [54-76] years) with 50 (476%) randomized to the control group and 55 (524%) to the colchicine group Median (interquartile range) peak high-sensitivity cardiac troponin values were 00112 (00043-00093) ng/mL in the control group and 0008 (0004-00135) ng/mL in the colchicine group (P = 34) Median (interquartile range) maximum C-reactive protein levels were 45 (14-89) mg/dL vs 31 (08-98) mg/dL (P = 73), respectively The clinical primary end point rate was 140% in the control group (7 of 50 patients) and 18% in the colchicine group (1 of 55 patients) (odds ratio, 011; 95% CI, 001-096;P = 02) Mean (SD) event-free survival time was 186 (083) days the in the control group vs 207 (031) in the colchicine group (log rankP = 03) Adverse events were similar in the 2 groups, except for diarrhea, which was more frequent with colchicine group than the control group (25 patients [455%] vs 9 patients [180%];P = 003) Conclusions and Relevance In this randomized clinical trial, participants who received colchicine had statistically significantly improved time to clinical deterioration There were no significant differences in high-sensitivity cardiac troponin or C-reactive protein levels These findings should be interpreted with caution Trial Registration ClinicalTrialsgov Identifier:NCT04326790
345 citations
••
TL;DR: The present review aims to give a researcher who has no experience with Photofuelcells all necessary basic knowledge to join the field without much trouble and to give to an experienced researcher a handy manual of reference.
342 citations
Authors
Showing all 13529 results
Name | H-index | Papers | Citations |
---|---|---|---|
Thomas J. Meyer | 120 | 1078 | 68519 |
Thoralf M. Sundt | 112 | 755 | 55708 |
Chihaya Adachi | 112 | 908 | 61403 |
Eleftherios P. Diamandis | 110 | 1064 | 52654 |
Roland Siegwart | 105 | 1154 | 51473 |
T. Geralis | 99 | 808 | 52221 |
Spyros N. Pandis | 97 | 377 | 51660 |
Michael Tsapatsis | 77 | 375 | 20051 |
George K. Karagiannidis | 76 | 653 | 24066 |
Eleftherios Mylonakis | 75 | 448 | 21413 |
Matthias Mörgelin | 75 | 332 | 18711 |
Constantinos C. Stoumpos | 75 | 194 | 27991 |
Raymond Alexanian | 75 | 211 | 21923 |
Mark J. Ablowitz | 74 | 374 | 27715 |
John Lygeros | 73 | 667 | 21508 |